Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy

BACKGROUND: Isocitrate dehydrogenase-2 (IDH2) is a mitochondrial enzyme that catalyzes the metabolic conversion between isocitrate and alpha-ketoglutarate (α-KG) in the TCA cycle. IDH2 mutation is an oncogenic event in acute myeloid leukemia (AML) due to the generation of 2-hydroxyglutarate. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Peiting, Lu, Wenhua, Tian, Jingyu, Qiao, Shuang, Li, Jiangjiang, Glorieux, Christophe, Wen, Shijun, Zhang, Hui, Li, Yiqing, Huang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935709/
https://www.ncbi.nlm.nih.gov/pubmed/35313945
http://dx.doi.org/10.1186/s13045-022-01245-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935709/
https://www.ncbi.nlm.nih.gov/pubmed/35313945
http://dx.doi.org/10.1186/s13045-022-01245-z

Ejemplares similares